Companies in the News

Indigo Corn™ Demonstrates Significant Yield Gains on Farms Experiencing Severe Water Stress

- Indigo Corn demonstrates a 30+ bushel per acre yield increase on farms under severe water stress - Indigo announces 47 cent per bushel premium at harvest for growers of Indigo Corn in 2018 Boston, Massachusetts, November 20, 2017 – Indigo Ag, Inc., a company dedicated to harnessing nature to help farmers sustainably feed the planet, has released preliminary data from its microbial seed treatment for corn. Indigo CornTM was commercially launched in the spring of 2017. Like Indigo WheatTM and Indigo CottonTM, Indigo Corn was developed from naturally occurring, in-plant microbes to increase the productivity of plants by improving their tolerance to water stress. With expected increases in b

eFFECTOR Therapeutics Presents Preclinical Data for eFT508 that Demonstrates Beneficial Immunologica

SAN DIEGO, November 10, 2017 – eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced a poster presentation of preclinical data for its lead product candidate, eFT508, that defines its immunological mechanism of action and activation of anti-tumor immune response. In vitro and in vivo preclinical models demonstrate eFT508 selectively downregulates key immune checkpoint proteins without compromising T cell activation or viability. These data are being presented at the Society for Immunotherapy of Cancer (SITC) 32nd annual meeting being held in National Harbor, Maryland on November 10-12, 2017. The poster

Millendo Therapeutics Announces Positive Topline Phase 2 Results of ATR-101 in Classic Congenital Ad

ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel treatments for endocrine diseases, today announced positive topline results from a Phase 2 proof-of-concept study of ATR-101 in classic congenital adrenal hyperplasia (CAH), a rare inherited endocrine disease characterized by abnormal hormone levels and overgrowth of the adrenal glands. In the Phase 2 study, 7 of the first 10 patients demonstrated a clear biological effect as measured by reductions in 17-hydroxyprogesterone (17-OHP), a key measure of disease control. Based on the trial results, Millendo ended the trial early and the U.S. Food and Drug Adminis